It has been documented that the use of the anti-IL-6 monoclonal antibody tocilizumab in AKI caused a 57% decrease in the area under the curve (AUC) of the simvastatin, which is a CYP3A4 substrate, increasing its elimination [14]. Here, IL6 is linked to acute kidney injury.